Listed by the USPTO as TIWARI, VYOMA SHUBHAM
Tech Center 1600 • Art Units: 1633 1634 1638
This examiner grants 32% of resolved cases
TIWARI, VYOMA SHUBHAM is assigned to USPTO tech center 1600 and art unit 1633. The record includes 56 resolved cases, an allowance rate of 32.1%, and a median of 1507 days to allowance. The interview lift is 47.4%, showing a positive relationship despite the lower overall allowance rate. The limited case base makes this a directional profile for prosecution planning.
The listed companies are The Regents of the University of California, Ksq Therapeutics Inc., and University of Florida Research Foundation Inc. The leading firms are KLARQUIST SPARKMAN, LLP, Knobbe, Martens, Olson & Bear, LLP, and STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C. University and therapeutic applicants may consider interviews important when developing a response strategy.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18870030 | CELL-FREE DNA CONCENTRATION IN HYPOTHERMIC MACHINE PERFUSATE AS A RAPID MARKER FOR KIDNEY GRAFT QUALITY | Non-Final OA | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED |
| 16929948 | High Specificity Genome Editing Using Chemically Modified Guide RNAs | Final Rejection | Agilent Technologies, Inc. |
| 18715678 | ISLET-LIKE ORGANOID EXPRESSING MONSTIM1 IN WHICH INSULIN SECRETION IS REGULATED BY OPTICAL STIMULATION | Non-Final OA | KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY |
| 18912410 | METHODS OF TREATING EGFRVIII EXPRESSING GLIOBLASTOMAS | Final Rejection | The Regents of the University of California |
| 17607354 | BEAD-FREE EX-VIVO EXPANSION OF HUMAN REGULATORY T CELLS | Final Rejection | The Regents of the University of California |
| 17218025 | TARGETED LIPID PARTICLES AND COMPOSITIONS AND USES THEREOF | Non-Final OA | Flagship Pioneering Innovations V, Inc. |
| 18652048 | PORCINE MUSCLE EXTRACELLULAR MATRIX-DERIVED HYDROGEL AND USES THEREOF | Non-Final OA | University of Connecticut |
| 16768462 | MAINTENANCE-AND-AMPLIFICATION METHOD AND DIFFERENTIATION INDUCTION METHOD FOR PRIMORDIAL GERM CELLS/PRIMORDIAL GERM CELL-LIKE CELLS | Final Rejection | KYOTO UNIVERSITY |
| 18839277 | AGENT FOR ENHANCING PRODUCTION OF VIRAL VECTOR AND METHOD FOR PRODUCING VIRAL VECTOR | Non-Final OA | NIPPON MEDICAL SCHOOL FOUNDATION |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy32.1% of resolved applications examined by Vyoma Shubham Tiwari were allowed (56 resolved cases), compared with 34.8% across Art Unit 1633 over the last five years.
This examiner's interview lift is +47.4 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Vyoma Shubham Tiwari took 1,507 days on average from filing to allowance.
Vyoma Shubham Tiwari examines applications in Art Unit 1633 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
